Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) updated on the commercial availability of the next-gen ‘cobas® HBV quantitative nucleic acid’ test. It is meant to be used on the cobas® 6800/8800 systems. The new products expand the viral load monitoring portfolio that is based on the advanced molecular diagnostic platforms developed by the company. The new assay provides extended coverage of Hepatitis B genotypes with high sensitivity.
The management view
Roland Diggelmann of Roche Diagnostics said that with the new assay, clinical labs now possess a highly strong and effective assay for quantifying HBV DNA. There is now a lower sample requirement for test. As a result, the physicians will have a new standard of flexibility. The assay is based on the viral load monitoring portfolio for the cobas® 6800/8800 Systems. These were introduced in the market in late 2014.
The 6800/8800 systems of cobas, together with viral load assay portfolio, can improve lab efficiencies. It will also offer rapid results that are vital to take informed treatment decisions. Both the products are made commercially available in markets by the company. Roche Management stated that the product recognize CE-Mark. As of now, the products are not made commercially available in the U.S.
Cobas® 6800/8800 Systems
These systems are fully automated solutions that assist in women’s health and microbiology tests, blood donor screening, and viral load monitoring. They are offered in high and medium throughput models. They are built on the famous Nobel-prize winning PCR technology. They deliver improved automation with shorter time to results. It is a convenient testing tool for users as it can enhance overall workflow efficiencies.
The systems that work on Roche’s advanced platforms deliver up to 96 results in about 3.5 hours. Both systems permit mixed batching, which makes its possible for laboratories to conduct up to 3 tests in the same run. There is no need of pre-sorting required during this time.